A recent study by European Parliament's Panel for the Future of Science and Technology (STOA) investigated the feasibility of creating a large-scale European public infrastructure aimed at addressing vulnerabilities linked to the research, development, production and distribution of medicines.

On this basis, STOA is organising a panel discussion which will bring together experts from biomedical research, representatives of the pharmaceutical industry, and EU and international public health experts. The aim is to discuss the state-of-play of the EU's current pharmaceutical strategy and explore policy options for strengthening EU preparedness and response, including the feasibility of creating an advanced EU pharmaceutical infrastructure for the research and development of novel medicines and treatments. The panel discussion will be moderated by Karin SIPIDO, Head of Experimental Cardiology at KU Leuven, and the panel includes representatives from the European Commission. You can follow remotely or you can join the debate live in Brussels. 

More information, the detailed programme and registration is available on the event's webpage.